中文摘要：

套细胞淋巴瘤（mantle cell lymphoma,MCL）是一种独特的B细胞淋巴瘤,占非霍奇金淋巴瘤（non-Hodgkin’s lymphoma,NHL）的3%-10%,除自体干细胞移植（ASCT）外,MCL无其它可治愈的手段。MCL多见于老年男性,多数老年患者常合并基础疾病而不能耐受大剂量化疗和ASCT。全文主要分析MCL的病理生理、治疗、风险分层、预后以及老年患者的治疗选择。

英文摘要：

Mantle cell lymphoma （MCL） is a relatively rare B-cell lymphoma,accounted for about 3%-10% of all non-Hodgkin＇s lymphoma （NHL）. There is no curative treatment,except allogeneic stem cell transplantation （ASCT） for patients with MCL. However,the majority patient of MCL is elderly men, and often accompanied with underlying diseases cannot tolerate high-dose chemother- apy and ASCT. The histological type, staging,risk stratification,prognosis and the treatment selec- tion for elderly of MCL were analyzed in this article.